SUZHOU, China, February 26, 2026
ImmVira Group announced encouraging preliminary clinical data for its oncolytic virus candidate MVR-T3011 in BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) at the 2026 ASCO Genitourinary (GU) Conference in San Francisco. Originally developed for BCG-unresponsive bladder cancer, MVR-T3011 has now been expanded into BCG-naïve patients, addressing a critical treatment gap caused by global Bacillus Calmette-Guérin (BCG) shortages and tolerability challenges. The data highlight strong early efficacy, favorable safety, and the potential for oncolytic immunotherapy to emerge as a viable alternative to standard intravesical BCG therapy.
Encouraging Recurrence-Free Survival Outcomes
The study enrolled 18 BCG-naïve high-risk papillary Ta/T1 NMIBC patients, treated with intravesical MVR-T3011 at two dose levels: 2×10⁹ PFU (n=3) and 1×10¹⁰ PFU (n=15). Among the 14 evaluable patients, results demonstrated promising durability. At the lower dose, the 12-month recurrence-free survival (RFS) rate reached 100% (3/3). At the higher dose, the 3-month RFS rate was 100% (11/11), with 6-month and 9-month RFS rates of 75% and 66.7%, respectively. Although later timepoint data remain preliminary due to small patient numbers, these findings suggest sustained disease control in a high-risk population.
Bladder cancer ranks among the most prevalent malignancies globally, with approximately 75% of cases classified as NMIBC, a subtype characterized by frequent recurrence and risk of progression. BCG remains the current standard of care for high-risk NMIBC; however, persistent supply shortages and adverse events have limited accessibility. In this context, therapies that can deliver durable tumor control while maintaining tolerability are of high clinical interest.
Favorable Safety Profile Supports Broader Development
Advertisement
Safety analysis showed that most treatment-emergent adverse events (TEAEs) were Grade 1 or Grade 2, and importantly, no treatment-related adverse events (TRAEs) were observed. This favorable safety profile aligns with earlier data in BCG-unresponsive cohorts and strengthens the rationale for expanding clinical development into broader patient populations. Given that NMIBC management often requires repeated intravesical treatments, tolerability is a critical factor in long-term adherence and real-world applicability.
The outpatient intravesical administration of MVR-T3011 further supports feasibility in routine urology practice. By offering a potentially well-tolerated alternative with durable immune activation, the therapy may address unmet needs in both newly diagnosed and recurrent high-risk patients.
HSV-1-Based “3-in-1” Oncolytic Immunotherapy
MVR-T3011 is built on a replication-competent HSV-1 backbone featuring a proprietary “3-in-1” design that combines direct tumor lysis with immune stimulation. The construct integrates anti-PD-(L)1 antibody expression and IL-12, enabling simultaneous activation of innate and adaptive immune responses within the tumor microenvironment. This multi-mechanistic approach distinguishes MVR-T3011 from conventional intravesical agents by coupling localized viral oncolysis with checkpoint modulation and cytokine-driven immune amplification.
Oncolytic immunotherapy has gained increasing attention as a strategy to overcome immune resistance and improve durability of response. By leveraging engineered viral platforms, companies aim to generate systemic anti-tumor immunity while maintaining localized treatment delivery.
The expansion of MVR-T3011 into BCG-naïve NMIBC patients represents a strategic evolution of ImmVira’s development program. As healthcare systems seek effective and accessible alternatives amid ongoing BCG shortages, these preliminary results position MVR-T3011 as a promising next-generation immunotherapy candidate pending validation in larger, controlled trials.
Source: ImmVira press release
